irinotecan has been researched along with dinoprostone in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (25.00) | 18.2507 |
| 2000's | 6 (50.00) | 29.6817 |
| 2010's | 3 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Bellman, K; Knegtel, RM; Settimo, L | 1 |
| Hamada, N; Ikari, A; Kakinoki, B; Sakai, H; Sato, T; Takeguchi, N; Yasue, M | 1 |
| Hayakawa, T; Kamataki, T; Kase, Y; Togashi, Y | 1 |
| Aburada, M; Hayakawa, T; Kamataki, T; Kase, Y; Komatsu, Y | 1 |
| Ikari, A; Sakai, H; Suzuki, T; Takeguchi, N | 1 |
| Cameron, IL; Hardman, WE; Moyer, MP | 1 |
| Davis, TW; Durham, WF; Horton, J; Levine, BD; Masferrer, JL; Salazar, VS; Trifan, OC; Zweifel, BS | 1 |
| Evans, JF; Kargman, S; Kelly, CR; Kwong, E; Lam, EC; Luk, P; Wolfe, MM; Yao, M; Zheng, Y | 1 |
| Albert, A; Chang, AJ; Liu, TC; Sangha, S; Wolfe, MM; Yao, M; Zhou, W | 1 |
| Altundag, K; Altundag, O; Gundeslioglu, O; Gunduz, M; Silay, YS; Yigitbasi, OG | 1 |
| Bujok, K; Fromm, MF; Glaeser, H; Mandery, K; Rau, TT; Schmidt, I; Schuh, W | 1 |
12 other study(ies) available for irinotecan and dinoprostone
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
Topics: Chemistry, Pharmaceutical; Forecasting; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Random Allocation | 2014 |
Thromboxane A2, released by the anti-tumour drug irinotecan, is a novel stimulator of Cl- secretion in isolated rat colon.
Topics: Animals; Antineoplastic Agents, Phytogenic; Benzimidazoles; Benzoxepins; Camptothecin; Carbachol; Chloride Channels; Chlorides; Colon; Cyclooxygenase Inhibitors; Dinoprostone; Female; Imidazoles; Indomethacin; Intestinal Mucosa; Irinotecan; Membrane Potentials; Nitrobenzoates; Patch-Clamp Techniques; Rats; Rats, Wistar; Receptors, Thromboxane; Tetrodotoxin; Thromboxane A2; Thromboxane-A Synthase | 1997 |
Relevance of irinotecan hydrochloride-induced diarrhea to the level of prostaglandin E2 and water absorption of large intestine in rats.
Topics: Animals; Antineoplastic Agents, Phytogenic; Body Weight; Camptothecin; Colon; Diarrhea; Dinoprostone; Enzyme Inhibitors; Intestinal Absorption; Intestine, Large; Irinotecan; Male; Rats; Rats, Wistar; Topoisomerase I Inhibitors; Water | 1997 |
Preventive effects of Hange-shashin-to on irinotecan hydrochloride-caused diarrhea and its relevance to the colonic prostaglandin E2 and water absorption in the rat.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Colon; Diarrhea; Dinoprostone; Dose-Response Relationship, Drug; Drugs, Chinese Herbal; Eating; Intestinal Absorption; Irinotecan; Male; Rats; Rats, Wistar; Topoisomerase I Inhibitors; Water; Weight Gain | 1997 |
Inhibition of thromboxane A(2)-induced Cl(-) secretion by antidiarrhea drug loperamide in isolated rat colon.
Topics: Animals; Antidiarrheals; Calcium; Camptothecin; Chlorides; Colon; Dinoprostone; Female; In Vitro Techniques; Irinotecan; Loperamide; Naloxone; Rats; Rats, Wistar; Thromboxane A2 | 2000 |
Consumption of an omega-3 fatty acids product, INCELL AAFA, reduced side-effects of CPT-11 (irinotecan) in mice.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Dinoprostone; Duodenum; Fatty Acids, Omega-3; Irinotecan; Liver; Male; Membrane Lipids; Mice; Organ Size | 2002 |
Cyclooxygenase-2 inhibition with celecoxib enhances antitumor efficacy and reduces diarrhea side effect of CPT-11.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Celecoxib; Colon; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Diarrhea; Dinoprostone; Drug Administration Schedule; Drug Synergism; HT29 Cells; Humans; Irinotecan; Isoenzymes; Male; Membrane Proteins; Mice; Mice, Inbred BALB C; Mice, Nude; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Rats; Rats, Sprague-Dawley; Sulfonamides; Weight Loss; Xenograft Model Antitumor Assays | 2002 |
Inhibition of cyclooxygenase-2 by rofecoxib attenuates the growth and metastatic potential of colorectal carcinoma in mice.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Combined Chemotherapy Protocols; beta Catenin; Camptothecin; Cell Division; Colorectal Neoplasms; Cyclin D1; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Cytoskeletal Proteins; Dinoprostone; Drug Synergism; Endothelial Growth Factors; Fluorouracil; Intercellular Signaling Peptides and Proteins; Interleukin-10; Interleukin-12; Irinotecan; Isoenzymes; Lactones; Liver Neoplasms, Experimental; Lymphokines; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Membrane Proteins; Mice; Mice, Inbred BALB C; Neoplasm Transplantation; Prostaglandin-Endoperoxide Synthases; Sulfones; Trans-Activators; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2003 |
Effects of nonselective cyclooxygenase inhibition with low-dose ibuprofen on tumor growth, angiogenesis, metastasis, and survival in a mouse model of colorectal cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Camptothecin; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dinoprostone; Dose-Response Relationship, Drug; Fluorouracil; HT29 Cells; Humans; Ibuprofen; Irinotecan; Lactones; Liver Neoplasms; Male; Membrane Proteins; Mice; Mice, Inbred BALB C; Mice, Nude; Neovascularization, Pathologic; Prostaglandin-Endoperoxide Synthases; Sulfones; Survival Analysis; Xenograft Model Antitumor Assays | 2005 |
Selenium supplementation may increase the efficacy of cetuximab in metastatic colorectal cancer patients.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticarcinogenic Agents; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Depression, Chemical; Dietary Supplements; Dinoprostone; Drug Synergism; ErbB Receptors; Humans; Irinotecan; Membrane Proteins; Models, Biological; Neoplasm Proteins; Organoplatinum Compounds; Oxaliplatin; Phosphorylation; Prostaglandin-Endoperoxide Synthases; Protein Processing, Post-Translational; Selenium; Selenomethionine; Signal Transduction | 2005 |
Interplay between the prostaglandin transporter OATP2A1 and prostaglandin E2-mediated cellular effects.
Topics: Camptothecin; Cell Movement; Cell Survival; Cyclic AMP; Dinoprostone; Gastric Mucosa; HEK293 Cells; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Immunohistochemistry; Interleukin-8; Irinotecan; Organic Anion Transporters; Receptors, Prostaglandin E, EP4 Subtype; RNA, Messenger; S Phase Cell Cycle Checkpoints; Up-Regulation | 2015 |